
Spectrum Pharmaceuticals SPPI
Quarterly report 2023-Q1
added 05-16-2026
Spectrum Pharmaceuticals Interest Expense 2011-2026 | SPPI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Spectrum Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.33 M | -10.9 M | -2.94 M | -8.89 M | 3.13 M | 8.07 M | 9.69 M | 9.21 M | 8.72 M | 217 K | -359 K | 280 K | 1.28 M | 662 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.69 M | -10.9 M | 918 K |
Quarterly Interest Expense Spectrum Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 248 K | - | -443 K | -3.76 M | -1.33 M | - | 9 K | -5.88 M | -2.08 M | - | -9.13 M | 3.94 M | -10.5 M | - | 793 K | 886 K | 873 K | - | 793 K | 886 K | 873 K | - | 7 M | 4.63 M | 2.3 M | - | 7.24 M | 4.8 M | 2.38 M | - | 6.86 M | 4.55 M | 2.26 M | - | 6.5 M | 4.3 M | 2.1 M | - | 742 K | -163 K | -1.32 M | - | 293 K | -1.51 M | 138 K | - | -144 K | 174 K | 520 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.24 M | -10.5 M | 805 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.69 | 2.74 % | $ 198 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 31.72 | 2.82 % | $ 2.11 B | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 93.62 | 1.49 % | $ 22.6 B | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 53.82 | 4.33 % | $ 4.84 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.76 | 3.96 % | $ 258 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 M | $ 0.75 | 9.65 % | $ 34.3 M | ||
|
Esperion Therapeutics
ESPR
|
3.49 M | $ 3.13 | 0.16 % | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
1.06 M | $ 31.98 | 2.21 % | $ 861 M | ||
|
Forte Biosciences
FBRX
|
-396 K | $ 21.97 | 0.14 % | $ 284 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
Galectin Therapeutics
GALT
|
2.79 M | $ 2.72 | -2.69 % | $ 174 M | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Hutchison China MediTech Limited
HCM
|
759 K | $ 11.78 | 0.26 % | $ 10.1 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | ||
|
Heron Therapeutics
HRTX
|
1.34 M | $ 0.9 | 1.45 % | $ 150 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
ImmuCell Corporation
ICCC
|
476 K | $ 10.62 | 1.1 % | $ 95.9 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.35 | -2.62 % | $ 5.51 M |